Beijing Konruns PharmaceuticalLtd Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 1/6
Beijing Konruns PharmaceuticalLtd's earnings have been declining at an average annual rate of -18.2%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 1.3% per year. Beijing Konruns PharmaceuticalLtd's return on equity is 4.2%, and it has net margins of 13.6%.
Wichtige Informationen
-18.2%
Wachstumsrate der Gewinne
-17.5%
EPS-Wachstumsrate
| Pharmaceuticals Wachstum der Industrie | 10.9% |
| Wachstumsrate der Einnahmen | -1.3% |
| Eigenkapitalrendite | 4.2% |
| Netto-Marge | 13.6% |
| Letzte Ertragsaktualisierung | 30 Sep 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Aufschlüsselung der Einnahmen und Ausgaben
Wie Beijing Konruns PharmaceuticalLtd Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Sep 24 | 846 | 115 | 584 | 63 |
| 30 Jun 24 | 874 | 137 | 573 | 78 |
| 31 Mar 24 | 954 | 166 | 611 | 85 |
| 31 Dec 23 | 920 | 150 | 589 | 95 |
| 30 Sep 23 | 999 | 146 | 568 | 99 |
| 30 Jun 23 | 946 | 112 | 560 | 91 |
| 31 Mar 23 | 876 | 81 | 532 | 91 |
| 31 Dec 22 | 867 | 101 | 528 | 87 |
| 30 Sep 22 | 801 | 114 | 528 | 91 |
| 30 Jun 22 | 726 | 130 | 453 | 84 |
| 31 Mar 22 | 755 | 130 | 460 | 103 |
| 31 Dec 21 | 810 | 148 | 481 | 102 |
| 30 Sep 21 | 855 | 179 | 505 | 98 |
| 30 Jun 21 | 916 | 180 | 568 | 110 |
| 31 Mar 21 | 949 | 216 | 603 | 96 |
| 31 Dec 20 | 809 | 183 | 533 | 93 |
| 30 Sep 20 | 855 | 204 | 550 | 89 |
| 30 Jun 20 | 870 | 220 | 562 | 94 |
| 31 Mar 20 | 944 | 249 | 587 | 104 |
| 31 Dec 19 | 1,066 | 266 | 678 | 109 |
| 30 Sep 19 | 1,038 | 311 | 684 | 131 |
| 30 Jun 19 | 1,029 | 313 | 669 | 116 |
| 31 Mar 19 | 982 | 273 | 669 | 91 |
| 31 Dec 18 | 973 | 264 | 657 | 80 |
| 30 Sep 18 | 897 | 215 | 587 | 40 |
| 31 Dec 17 | 591 | 479 | 322 | 32 |
| 31 Dec 16 | 346 | 192 | 102 | 38 |
| 31 Dec 15 | 436 | 195 | 185 | 39 |
Qualität der Erträge: 603590 has high quality earnings.
Wachsende Gewinnspanne: 603590's current net profit margins (13.6%) are lower than last year (14.7%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: 603590's earnings have declined by 18.2% per year over the past 5 years.
Beschleunigtes Wachstum: 603590's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Erträge im Vergleich zur Industrie: 603590 had negative earnings growth (-21.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: 603590's Return on Equity (4.2%) is considered low.